Ann: Acrux's fifth generic dossier accepted by FDA for review, page-23

  1. 6,588 Posts.
    lightbulb Created with Sketch. 53
    I've come to the same conclusion as MarsC. As for being cashflow positive, ACR have had ample time to inform shareholders how our testosterone generic is going. Dash Pharma would know how it's going after some 8-9 months, and if it wasn't working out for them they certainly would have told ACR by now. So whilst not expecting much, any good news will surprise. It's some 7-8 years since this path was taken and we are getting close to the Day of Truth.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
2.0¢
Change
0.000(0.00%)
Mkt cap ! $7.747M
Open High Low Value Volume
2.0¢ 2.0¢ 1.9¢ $13.65K 683.1K

Buyers (Bids)

No. Vol. Price($)
4 571000 1.9¢
 

Sellers (Offers)

Price($) Vol. No.
2.0¢ 234041 2
View Market Depth
Last trade - 12.14pm 18/06/2025 (20 minute delay) ?
ACR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.